PQR6XX (mTOR)

You may also be interested in

Dipraglurant (mGlu5 NAM) for PD-LID

Milestone: Indication under evaluation Dipraglurant is a novel orally available highly selective metabotropic glutamate receptor subtype 5 negative allosteric modulator (mGlu5 NAM) which has completed Phase 1 and demonstrated efficacy in a Phase 2a proof of concept study for the treatment of levodopa-induced dyskinesia associated with Parkinson’s disease (PD-LID).

Phase II started

Herzuma (trastuzumab)

Multiple indications in metastatic breast cancer, early breast cancer and metastatic gastric cancer

Marketed

Truxima (rituximab)

Multiple indications in Non-Hodgkin's lymphoma (NHL), Chronic lymphocytic leukaemia (CLL), Rheumatoid arthritis, Granulomatosis with polyangiitis and microscopic polyangiitis and Pemphigus vulgaris